Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novavax cuts 2024 revenue forecast
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
(Reuters) -
Novavax
cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi. Shares of the U.S. biotech firm fell 3% to $8.73.
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax falls after guidance cut on lower vaccine sales
Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 financials, cut its full-year revenue guidance, citing a gloomy sales outlook for its COVID-19 vaccine,
Novavax Gets FDA Approval To Resume Testing 2 Vaccines
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax
has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long clinical hold. The FDA initially ...
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after identifying a safety concern.
Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold
Key Takeaways Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.Regulators stopped testing last month as one patient had a serious adverse event after taking the shot.
Q3, Novavax
Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript
Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET
Novavax: Q3 Earnings Snapshot
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 76 cents.
Spotify: Q3 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.75 per share.
Hosted on MSN
15h
Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
Novavax
Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
5h
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
AOL
15h
Novavax: Stock plunges after quarterly earnings, but sees hope in licensing deals
Novavax
's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
16h
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...
12h
Novavax cuts FY24 revenue view to $650M-$700M from $700M-$800M
FY24 consensus $761.46M. Cuts FY24 product sales view to $175M-$225M from $275M-$375M. Raises FY24 Licensing, Royalties and Other Revenue view ...
FiercePharma
6d
Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
Yahoo Finance
17h
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
GAITHERSBURG, Md., Nov. 12, 2024 /PRNewswire/ --
Novavax
, Inc. (Nasdaq: NVAX), a global company advancing protein-based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
COVID
Food and Drug Administration
FDA
United States
NVAX
Feedback